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 Background: Brain death initiates hemodynamic, immunological, and hormonal changes that potentially compromise organ 
quality for transplantation. Therefore, it is generally believed that organs should be procured as soon as pos-
sible after the declaration of brain death. However, conflicting data exist regarding the impact of brain death 
duration on long-term graft function and survival.
 Material/Methods: The effect of duration of brain death on graft survival and function of 1869 adult transplant recipients receiving 
kidneys from deceased donors after brain death was analyzed, using relevant donor and recipient characteris-
tics and allograft related factors.
 Results: Duration of brain death was a significant predictor for long-term graft survival, whilst there was no significant 
effect of duration of brain death on the incidence of delayed graft function or acute graft rejection after kid-
ney transplantation. After dividing the study population into a “short durBD” (<10.6 hours) group and a “long 
durBD” (>10.6 hours) group, the 15-year graft survival estimates were significantly higher and the serum cre-
atinine at 3 months after transplantation was significantly lower in the “long durBD” group.
 Conclusions: Duration of brain death does not affect the incidence of delayed graft function or acute rejection after kidney 
transplantation. However, longer duration of brain death is associated with better kidney allograft function and 
survival.
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Background
The immunological changes and hormonal dysregulation in 
brain-dead donors may contribute to the inferior outcomes 
of transplantation with a kidney from a brain-dead donor as 
compared to a kidney from a living donor [1–3]. This can be 
explained by the hemodynamic instability in the donor: when 
cerebral ischemia reaches the medulla oblongata, the sympa-
thetic nerves are excited, causing the explosive release of en-
dogenous catecholamines. This leading to an abrupt elevation of 
blood pressure and tachycardia, also called the “sympathetic or 
catecholamine storm”. The release of catecholamines increases 
the heart load and oxygen consumption. High levels of cate-
cholamines can also lead to overload of intracellular calcium, 
depletion of adenosine triphosphate, and therefore overpro-
duction of oxygen free radicals and cell injury. Thereafter, a hy-
potensive phase commences, due to gradual depletion of cat-
echolamines, causing further reduction of the oxygen supply 
to the internal organs [4,5]. Therefore, it is generally believed 
that organs should be procured as soon as possible once brain 
death is confirmed. This is supported by evidence from ani-
mal studies indicating that prolonged duration of brain death 
(durBD) is deleterious [6–8]. However, evidence from clinical 
cohort studies indicates that longer durBD is not detrimen-
tal, but beneficial by reducing the incidence of delayed graft 
function [9–12]. Conflicting evidence exists regarding the influ-
ence of brain death duration on long-term kidney graft func-
tion and survival [10,12].
We aimed to study the impact of brain death duration on 
long-term outcome in deceased donor kidney transplanta-
tion. Therefore, we analyzed data from the Netherlands Organ 
Transplant Registry (NOTR).
Material and Methods
Patients
Data was obtained from a prospectively maintained electronic 
database called the Netherlands Organ Transplant Registry 
(NOTR, Dutch Transplant Foundation, Leiden, the Netherlands). 
The dataset that we used included a consecutive series of do-
nation after brain death kidney transplantations from May 1, 
2002 to December 31, 2015 in the Netherlands. Inclusion cri-
teria were: initial kidney transplantation in adult recipients 
aged ³18 years with recorded data of durBD, immediate or 
delayed graft function, graft rejection within the first year af-
ter kidney transplantation, and graft survival.
The following characteristics were available and extracted from 
the database: donor age, gender, body mass index, hypotensive 
period(s) and lowest creatinine during the brain death period, 
history of systemic diseases (e.g., hypertension, diabetes mel-
litus), date and time of brain death declaration and start of 
cold perfusion; recipient gender, age, body mass index and du-
ration of dialysis prior to kidney transplantation; anastomosis 
time, cold ischemia time and human leukocyte antigen mis-
matches. DurBD was calculated by subtracting the time of start 
of cold perfusion and the time of declaration of brain death.
Endpoints
The long-term outcome measure was graft survival. Graft failure 
was defined as the return to dialysis or re-transplantation and 
was censored upon death with a functioning graft. The short-
term outcome measures were delayed graft function, defined 
as the need for dialysis after transplantation; acute rejection, 
defined as the need for treatment for graft rejection within 
the first year after kidney transplantation; serum creatinine 3 
and 12 months after kidney transplantation.
Risk of bias
To address potential sources of bias, baseline donor and re-
cipient characteristics and allograft related factors of exposed 
and unexposed participants were compared, and follow-up out-
come data on immediate or delayed graft function, graft rejec-
tion within the first year after kidney transplantation, and graft 
survival were considered for selection bias; multivariable anal-
ysis with relevant donor and recipient demographics and al-
lograft related were performed for confounding factors [13–18].
Statistical analysis
To evaluate the effect of durBD on graft survival after kidney 
transplantation, uni- and multivariable Cox proportional haz-
ards models were performed with relevant donor and recipient 
characteristics and allograft related factors. Binary logistic re-
gression, with relevant donor and recipient characteristics and 
allograft related factors, was used to identify whether durBD 
was associated with the incidence of delayed graft function or 
acute rejection. After measuring the effect of durBD as a con-
tinuous variable, we divided our study population equally by 
the median in the “short durBD” (<10.6 hours) group and the 
“long durBD” (>10.6 hours) group [10]. The effect of “short 
durBD” versus “long durBD” on graft survival was expressed 
graphically using the Kaplan-Meier method for illustrational 
purposes; the statistical difference between groups was as-
sessed by the log-rank test. The effect on serum creatinine 
3 and 12 months post-operatively was evaluated using the 
Mann-Whitney U test. All statistical analyses were performed 
using SPSS software, version 25 (SPSS Inx., Chicago, IL, USA). 
P-values <0.05 were considered statistically significant.
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Results
Demographics
Between May 1, 2002 and December 31, 2015 there were 2460 
initial transplantations performed with kidneys donated after 
brain death, in adults in the Netherlands, including 1869 trans-
plants with recorded data of durBD. Data on time of start of 
cold perfusion or time of declaration of brain death was not 
recorded for 591 transplants (24.0%), and these transplants 
where therefore excluded. Data on graft function and/or graft 
survival was not recorded for 286 transplant recipients (15.3%) 
who were lost to follow-up. Therefore, 1583 donor-recipient 
pairs were included in this analysis. Demographics of donors 
and recipients, and allograft-related factors are shown in 
Table 1. The median durBD was 10.6 hours; the distribution of 
durBD is shown in Figure 1. For 99.0% of all donors the durBD 
was shorter than 24 hours.
Duration of brain death and graft function
Data on direct or delayed graft function after kidney transplan-
tation were available for 1583 recipients (84.7%). Donors of 
these recipients who had immediate graft function (n=1306) 
had a median durBD of 10.7 hours (range, 9.0 to 12.5 hours), 
while donors of recipients who suffered from delayed graft func-
tion (n=277) had a median durBD of 10.5 hours (range, 8.9 to 
12.8 hours). In recipients who needed treatment for rejection 
Baseline characteristics
Included pairs 
(n=1,869)
n
Excluded pairs
(n=591)
n P-value
Duration of brain death period (hours)  10.6 (8.9–12.5) 1,869 N/A 591 N/A
Donor gender (Male)  833 (44.6%) 1,869  313 (53.0%) 591 .000
Donor age (years)  54 (45–63) 1,869  51 (42–58) 591 .000
Donor body mass index (kg/m2)  24.5 (22.5–26.9) 1,869  25.1 (23.3–27.8) 591 .000
Expanded criteria donor  696 (37.2%) 1,869  157 (26.6%) 591 .000
Donor history of hypertension  505 (28.0%) 1,806  179 (42.3%) 423 .000
Donor hypotensive period(s)  658 (37.3%) 1,762  122 (34.2%) 357 .252
Donor history of diabetes mellitus  24 (1.3%) 1,859  0 (0.0%) 19 .618
Donor history of cardiac arrest  449 (24.4%) 1,843  76 (20.1%) 378 .064
Donor use of inotropic medication  1,616 (86.5%) 1,869  22 (95.7%) 23 .049
Donor cause of death: stroke  587 (31.4%) 1,869  163 (27.6%) 591 .073
Donor cause of death: trauma  290 (15.5%) 1,869  89 (15.1%) 591 .789
Donor lowest creatinine (µmol/L)  64 (50–100) 1,868  69 (53–104) 591 .707
Recipient gender (Male)  1,151 (61.6%) 1,869  300 (50.8%) 591 .000
Recipient age (years)  57 (45–65) 1,869  54 (44–61) 591 .000
Recipient body mass index (kg/m2)  25.4 (22.8–28.4) 1,725  24.8 (22.2–28.1) 564 .181
Recipient dialysis duration (years)  3.67 (2.42–4.99) 1,702  2.98 (1.90–4.58) 542 .017
Cold ischemia time (hours)  14.6 (11.5–19.0) 1,665  18.0 (14.5–22.7) 551 .000
Anastomosis time (minutes)  33 (26–40) 1,662  32 (25–40) 534 .376
Number of HLA mismatches  3 (2–4) 1,859  2 (0–3) 589 .000
Delayed graft function  277 (17.5%) 1,583  82 (16.0%) 513 .429
Acute graft rejection within 1 year  110 (5.9%) 1,869  38 (6.4%) 591 .628
Graft failure  293 (15.7%) 1,869  100 (16.9%) 591 .472
Table 1. Baseline donor and recipient demographics and allograft related factors (n=2460).
Values are expressed as the median (25th–75th percentile), unless stated otherwise. HLA – human leukocyte antigen.
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Figure 1.  Distribution of duration of brain death 
period in hours.
Graft function
Delayed graft function Acute graft rejection
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Duration of brain death period (hours)  1.042 (0.999–1.087) .058  1.054 (0.999–1.112) .055
Donor gender (Female/Male)  1.569 (1.128–2.183) .008  0.942 (0.588–1.508) .804
Donor age (years)  1.036 (1.015–1.057) .001  1.034 (1.003–1.067) .033
Donor body mass index (kg/m2)  1.044 (1.004–1.086) .031  1.006 (0.952–1.062) .841
Expanded criteria donor  0.955 (0.564–1.617) .863  0.975 (0.459–2.069) .948
Donor history of hypertension  1.365 (0.946–1.970) .096  0.663 (0.380–1.158) .149
Donor hypotensive period(s)  0.774 (0.547–1.095) .148  1.027 (0.633–1.667) .915
Donor history of diabetes mellitus  0.671 (0.078–5.791) .717  1.595 (0.195–13.039) .663
Donor history of cardiac arrest  1.461 (0.992–2.152) .055  0.895 (0.501–1.598) .707
Donor use of inotropic medication  1.238 (0.744–2.061) .411  1.240 (0.595–2.582) .566
Donor cause of death: stroke  0.709 (0.482–1.043) .081  0.832 (0.492–1.407) .493
Donor cause of death: trauma  1.069 (0.662–1.727) .784  0.502 (0.223–1.131) .096
Donor lowest creatinine (µmol/L)  1.001 (1.000–1.001) .079  1.001 (1.000–1.001) .029
Recipient gender (Female/Male)  1.307 (0.930–1.839) .123  1.496 (0.910–2.461) .112
Recipient age (years)  0.996 (0.982–1.010) .595  0.992 (0.973–1.012) .433
Recipient body mass index (kg/m2)  1.083 (1.043–1.124) .000  1.038 (0.984–1.095) .175
Recipient dialysis duration (years)  1.196 (1.100–1.300) .000  0.970 (0.857–1.098) .633
Cold ischemia time (hours)  1.050 (1.022–1.078) .000  1.023 (0.984–1.095) .245
Anastomosis time (minutes)  1.002 (0.989–1.015) .761  0.987 (0.968–1.007) .195
Number of HLA mismatches  1.038 (0.915–1.177) .562  0.988 (0.829–1.176) .888
Table 2. Multivariable binary logistic regression analysis for delayed graft function and acute graft rejection.
HLA – human leukocyte antigen.
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within 1 year after transplantation (n=110), the donors had 
a median durBD of 10.2 hours (range, 9.0 to 12.5 hours), while 
durBD was 10.7 hours (range, 8.9 to 12.5 hours) in donors of 
rejection-free recipients (n=1759).
To evaluate the effect of durBD on the incidence of delayed graft 
function and acute rejection, binary logistic analyses with rele-
vant donor and recipient characteristics and allograft related fac-
tors were performed. In a univariable logistic regression analysis, 
the effect of durBD was not significant for the incidence of de-
layed graft function with an odds ratio (OR) of 1.012 (P=0.503) 
or the incidence of graft rejection in the first year after trans-
plantation with an OR of 1.012 (P=0.641). In a multivariable lo-
gistic regression analysis, the effect of durBD remained nonsig-
nificant for the incidence of delayed graft function with an OR of 
1.042 (P=0.058) or acute rejection with an OR of 1.054 (P=0.055). 
Table 2 shows the variables used in the multivariable analysis.
To identify factors influencing durBD, we entered each vari-
able separately into the regression model. Donor age was the 
only factor that significantly influenced durBD. Subsequently, 
we tested the correlation between durBD and donor age. 
These variables were correlated with a Pearson’s coefficient 
of –0.144 (P=0.000), indicating donors with a prolonged durBD 
were younger of age.
We divided our study population equally by the median in a “short 
durBD” (<10.6 hours) group and “long durBD” (>10.6 hours) group. 
At 3 months after transplantation, serum creatinine was signif-
icantly lower in the “long durBD” group: “short durBD” group 
138 µmol/L (range, 110 to 175 µmol/L) versus “long durBD” group 
132 µmol/L (range, 106 to 162 µmol/L), P=0.003. At twelve months 
after transplantation, there was no significant difference: “short 
durBD” 133 µmol/L (range 107 to 168 µmol/L) versus “long durBD” 
129 µmol/L (range, 107 to 159 µmol/L), P=0.085.
Duration of brain death and graft survival
Recipients with functioning grafts after transplantation (84.2%) 
had kidneys from donors with a median durBD of 10.7 hours 
Graft survival Hazard ratio (95% CI) P-value
Duration of brain death period (hours)  0.933 (0.882–0.987) .015
Donor gender (Female/Male)  1.247 (0.870–1.789) .230
Donor age (years)  1.035 (1.012–1.058) .003
Donor body mass index (kg/m2)  0.965 (0.923–1.009) .120
Expanded criteria donor  1.203 (0.699–2.073) .505
Donor history of hypertension  1.164 (0.781–1.733) .456
Donor hypotensive period(s)  0.921 (0.640–1.325) .657
Donor history of diabetes mellitus  5.415 (1.608–18.237) .006
Donor history of cardiac arrest  1.213 (0.802–1.835) .360
Donor use of inotropic medication  1.886 (0.994–3.578) .088
Donor cause of death: stroke  0.611 (0.398–0.937) .024
Donor cause of death: trauma  0.812 (0.481–1.370) .435
Donor lowest creatinine (µmol/L)  1.001 (1.000–1.001) .013
Recipient gender (Female/Male)  1.088 (0.755–1.567) .651
Recipient age (years)  0.973 (0.959–0.987) .000
Recipient body mass index (kg/m2)  1.008 (0.966–1.051) .726
Recipient dialysis duration (years)  0.996 (0.903–1.099) .939
Cold ischemia time (hours)  1.015 (0.987–1.045) .286
Anastomosis time (minutes)  0.994 (0.980–1.007) .336
Number of HLA mismatches  0.927 (0.808–1.064) .283
Delayed graft function  2.279 (1.541–3.369) .000
Acute graft rejection within 1 year  4.122 (2.541–6.686) .000
Table 3. Multivariable Cox proportional hazards analysis for graft survival.
HLA – human leukocyte antigen.
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(range, 9.0 to 12.6 hours), while recipients with graft failure 
had donors with a median durBD of 10.1 hours (range, 8.2 to 
12.0 hours).
Using the Cox proportional hazards model, the effect of durBD 
on the graft survival after kidney transplantation was ana-
lyzed with relevant donor and recipient characteristics and 
allograft related factors. In a univariable Cox analysis, durBD 
influenced the graft survival significantly with a hazard ratio 
(HR) of 0.941 (P=0.001). In a multivariable Cox analysis, durBD 
remained a significant independent predictor for graft survival 
after kidney transplantation with a HR of 0.933 (P=0.015). 
Table 3 shows the variables used in the multivariable analysis.
After dividing our study population equally by the median in 
a “short durBD” (<10.6 hours) group and a “long durBD” (>10.6 
hours) group, Kaplan-Meier analysis showed that the 15-year 
graft survival (Figure 2) was significantly higher for recipients 
whom received a kidney from a donor with “long durBD” com-
pared to a kidney received from a donor with a “short durBD” 
with a log rank of 6.094 (P=0.014). The estimated 15-year 
death-censored graft survival was 73.8%, for kidneys from do-
nors with “short durBD” and 79.5% for kidneys from donors 
with “long durBD”.
Discussion
We show that prolonged durBD was a significant independent 
predictor for better graft survival after kidney transplantation. 
Since brain death has well known deleterious hemodynamic 
effects, it seems logical to remove donor organs as soon as 
possible after brain death has been established. However, our 
data suggest that longer duration of brain death in the do-
nor was not detrimental, but was correlated with better graft 
survival after kidney transplantation. At 3 months after trans-
plantation, “long durBD” was associated with lower creatinine 
indicating better graft function. There was no association be-
tween duration of brain death and incidence of delayed graft 
function or acute rejection.
In 2001, Muruve et al. performed the first study comparing the 
effect of durBD on graft survival [9]. The authors retrospec-
tively analyzed the effect of durBD on graft survival of 627 do-
nor-recipient pairs with “short durBD (<24.7 hours), “medium 
durBD” (24.7 to 59.2 hours), and “long durBD” (>59.2 hours). 
Using the univariate analyses, durBD had no significant effect 
on graft survival 1 year and 10 years after kidney transplanta-
tion. In the same year, Kunzendorf et al. performed a similar 
study and concluded that kidney allografts procured from do-
nors with “long durBD” (>7.8 hours) in comparison to “short 
durBD” (<7.8 hours), exhibited a significantly better graft sur-
vival 10 year after kidney transplantation and lower incidence 
of delayed graft function [10]. In our view, it is important to 
note that Kunzendorf et al. only performed a Kaplan-Meier sur-
vival analysis. Therefore, their data did not show that “long 
durBD” was an independent predictor of long-term graft sur-
vival. In 2007, Guner et al. performed a retrospective analysis 
of 24 donor-recipient pairs with “short durBD” (<12 hours) 
and “long durBD” (>12 hours), according to their observation 
that 12 hours was the period usually required to stabilize the 
condition of the brain-dead organ donor [11]. Serum creati-
nine at 3 months after kidney transplantation was significantly 
lower in the “long durBD” group. There was no difference in 
serum creatinine at 12 months post kidney transplantation. 
In 2010, a retrospective analysis of the Organ Procurement 
and Transplant Network was performed by Nijboer et al. for 
20 773 donor-recipient pairs [12]. A multivariate Cox regres-
sion hazards model and multivariate binary logistics regres-
sion indicated that the effect of durBD was not significant for 
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survival.
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graft survival at 1 year and 3 years after kidney transplanta-
tion or for the incidence of delayed graft function, respectively.
A beneficial effect of long durBD is contra-intuitive, since brain 
death causes hemodynamic changes, hormone dysregulation, 
a pro-inflammatory environment, and apoptosis of liver and 
kidney cells [2,18–20]. There are several possible explanations 
for this paradox. First, longer durBD implies longer stay at the 
intensive care unit and therefore more opportunity to coun-
terbalance the effects of a hypotensive period. However, in 
our series, we did not find that hypotensive period(s) during 
brain death modulated the effects of durBD on graft function 
and long-term graft survival.
Second, a longer durBD could provide opportunity for the do-
nor organs to recover from the catecholamine storm. A study 
in rats showed that there is a continuous deterioration of liver 
and kidney function from 1 to 6 hours after brain death, but, 
provided that the donor is hemodynamically stable, no further 
deterioration occurs in the subsequent 5 hours [21].
Moreover, there is increasing evidence that the application of 
brief, non-lethal periods of ischemia and reperfusion, activates 
an innate immune response that confers protection against 
later prolonged periods of ischemia. These effects are also 
present in remote areas, called “remote ischemic precondi-
tioning” [22]. Kunzendorf et al. suggested that the sublethal 
ischemia of organs due to brain death can lead to ischemic 
preconditioning, and therefore have protective effects on the 
kidney allograft [10].
Strengths and limitations
An important strength of this study was the use of a large co-
hort and the fact that the data were collected in a prospective 
manner. However, data were obtained from multiple centers, 
which implies multiple protocols with respect to the trans-
plantation procedure. This could have introduced some het-
erogeneity. Also, durBD was defined as the interval between 
declaration of donor brain death and start of cold perfusion. 
This could have caused some underestimation of the durBD 
since brain death can already be present before it is formally 
established. It should also be noted that the durBD in the 
United States, as shown by Muruve et al. (median durBD 24.7 
to 59.2 hours) and Nijboer et al. (median durBD 23.8 hours), 
are generally longer when compared to Europe, as shown by 
Kunzendorf et al. (median durBD 7.8 hours). This is probably 
due to the fact that in the United States more time is spent to 
obtain informed consent for donation and because multi-organ 
procurement is usually planned during office hours. Whereas 
in Europe the surgery of the donor is commonly performed as 
soon as possible, often during the night [12]. Since the 2 larg-
est studies comparing the impact of durBD on graft survival 
were performed with data from the United States, it is difficult 
to compare these outcomes with our data [9,12].
Conclusions
In conclusion, we showed that prolonged duration of brain 
death is a significant independent predictor for better long-
term kidney graft survival. There was no significant effect of 
duration of brain death period on the incidence of delayed graft 
function or acute rejection within 1 year after kidney trans-
plantation, but kidney function at 3 months after transplan-
tation was better in the “long durBD” group. Therefore, our 
recommendation is to optimize donor management, in con-
trast to procuring the organs as fast as possible. Further re-
search is necessary to unravel the mechanism of this effects 
and to define the optimal duration of the brain death period.
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